Ready-Made immune cells take on lymphoma and leukemia in first human trial
NCT ID NCT07518329
First seen Apr 16, 2026 · Last updated May 25, 2026 · Updated 4 times
Summary
This early-phase study tests a new treatment called ALA-101 for people with certain types of blood cancer (non-Hodgkin lymphoma and leukemia). ALA-101 uses specially engineered immune cells from a healthy donor that are designed to find and attack cancer cells. The main goal is to check safety and find the best dose, with 46 adults expected to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA (NHL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Epworth HealthCare
Richmond, Victoria, 3121, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.